Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
SAN RAFAEL, Calif. April 12, 2024 - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading provider of exoskeleton technology for medical and industrial applications, is pleased to announce a significant milestone in its mission to improve mobility and quality of life for individuals with spinal cord injuries. The Centers for Medicare & Medicaid Services (CMS) has reached a final payment determination for Medicare reimbursement of the Ekso Indego Personal exoskeleton.
The Pricing, Data Analysis, and Coding (PDAC) contractor for the CMS has established a reimbursement rate of $91,031.93 for the Ekso Indego Personal, effective from April 1, 2024. This remarkable news reinforces Ekso Bionics’ position as an innovator and industry leader in exoskeleton technology.
The Ekso Indego Personal exoskeleton is a game-changer for individuals with spinal cord injuries, as it empowers them to regain mobility and independence. By providing mechanical support and enabling users to walk again, the exoskeleton significantly enhances their quality of life.
Medicare reimbursement for the Ekso Indego Personal is a critical step towards making this groundbreaking technology more accessible to those who need it the most. With the CMS recognizing the value and potential impact of the Ekso Indego Personal, individuals with spinal cord injuries can now hope for a brighter future, where exoskeleton technology becomes a standard part of their rehabilitation programs.
The final payment determination by the PDAC contractor represents a significant achievement for Ekso Bionics, validating the effectiveness, safety, and value of the Ekso Indego Personal exoskeleton. It showcases Ekso Bionics’ commitment to bridging the gap between innovative technology and patient care, ensuring that life-changing solutions reach those who can benefit from them.
While the reimbursement rate is essential, it is equally important to acknowledge the immense potential of the Ekso Indego Personal exoskeleton. The technology not only provides physical support but also offers psychological benefits by restoring mobility, independence, and confidence to those struggling with spinal cord injuries.
With this development, Ekso Bionics expects to witness accelerated adoption of its exoskeleton technology in medical facilities across the country. This reimbursement decision reinforces the Company’s dedication to providing innovative and sustainable solutions that address the unmet needs of patients with spinal cord injuries.
In conclusion, the final payment determination for Medicare reimbursement of the Ekso Indego Personal exoskeleton is a significant achievement for Ekso Bionics. This decision paves the way for greater accessibility and affordability of exoskeleton technology, facilitating improved rehabilitation and enhanced quality of life for individuals with spinal cord injuries. Ekso Bionics continues to lead the industry in translating groundbreaking innovation into practical solutions that transform lives.
(
Comments